Fragment 176-191, a modified version of AOD-9604, is a small portion of human growth hormone known as the "lipolytic fragment." Animal studies have shown that it can promote fat burning, particularly in mice bred to have high levels of body fat.
Unlike its parent protein, fragment 176-191 has been found to avoid certain effects, such as increasing insulin-like growth factor-1 (IGF-1) levels, affecting carbohydrate metabolism, reducing insulin sensitivity, and promoting long bone growth. As a result, it is being investigated as a potential tool for studying human fat metabolism and for developing anti-obesity drugs.
Fragment 176-191 is mainly being researched for its weight loss and lipolysis properties, with a significant focus on understanding fat metabolism and energy homeostasis. The peptide is also being studied for its potential to promote cartilage repair and connective tissue regeneration.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
hGH Frag 176-191, also known as Frag 176-191, is a high-purity research peptide corresponding to the C-terminal segment of human growth hormone associated with lipolytic signaling. This fragment is synthesized for controlled laboratory studies evaluating fat metabolism, energy balance, and receptor-mediated signaling pathways in preclinical research models.
hGH Frag 176-191 Research Peptide Specifications:
| Unit Size | 6 mg/vial |
| Unit Quantity | 1 vial |
| Purity (HPLC) | > 99% |
| Sequence | Phe–Leu–Arg–Ile–Val–Gln–Cys–Arg–Ser–Val–Glu–Gly–Ser–Cys–Gly–Phe |
| Molecular Formula | C78H123N23O22S2 |
| Molecular Weight | ≈ 1,799.1 g/mol |
| CAS Number | 66004-57-7 |
| Appearance | Lyophilized white powder |
| Source | Chemical synthesis |
| Storage Conditions | Store lyophilized Frag 176-191 at -20 °C, protected from light and moisture. Reconstituted peptide may be stored at 4 °C for short-term research use. |
| Research Use Only | This research peptide is intended for laboratory research use only. Not for human consumption or therapeutic use. Please review our terms of service prior to ordering. |
Frag 176-191 is a synthetic peptide corresponding to amino acids 176–191 of the human growth hormone (hGH) molecule. This C-terminal region has been identified in preclinical studies as a key segment associated with lipolytic and anti-lipogenic activity, distinct from the broader somatotropic effects of full-length hGH.1,2
By isolating this specific region, researchers can interrogate fat-metabolism pathways without engaging the full spectrum of growth hormone signaling. In rodent and cell-culture models, synthetic fragments derived from this domain have been investigated for their impact on lipid mobilization, fatty-acid oxidation, and adipocyte signaling cascades under controlled conditions.2,3
Laboratory data suggest that Frag 176-191 may selectively engage lipolytic pathways, supporting investigations into how this region of hGH interfaces with β-adrenergic signaling, cyclic AMP (cAMP) production, and downstream protein kinase A (PKA)–mediated events in adipose tissue. This makes Frag 176-191 a useful probe for dissecting the mechanistic separation between growth, metabolic, and body-composition–related signaling modes in preclinical research.
In parallel, in silico and in vitro work has explored potential roles for hGH C-terminal fragments in broader contexts such as cellular stress responses, experimental oncology models, and combination strategies with other agents (for example, pairing with chemotherapeutic-loaded nanoparticles) to deepen understanding of receptor binding and combinatorial signaling effects in mammalian systems.1
Important Research Notice: Nordsci research peptides are manufactured under stringent quality-control processes and verified by independent third-party analytical testing. Each lot is supported by Certificate of Analysis (COA) documentation detailing identity and purity metrics for laboratory use.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
Reconstitution Guidelines for Laboratory Use:
For typical research applications, researchers may reconstitute each 5mg vial of Frag 176-191 with sterile bacteriostatic water to achieve the desired working concentration for experimental protocols.
Research Reference Considerations: Published studies have leveraged various concentration ranges and exposure schedules when evaluating hGH fragments in adipose tissue, metabolic, and cell-culture models. Laboratories should align test conditions with institutional protocols, species-specific guidelines, and current literature when designing experiments.
Note: The information above is provided for scientific context only. All work must be conducted by qualified personnel in appropriately equipped facilities operating under applicable animal-care, biosafety, and institutional review requirements.
Lipid Metabolism and Energy Balance: Frag 176-191 is widely used in preclinical research focused on lipolysis, lipogenesis, and adipocyte biology. Studies with related hGH-derived fragments have explored weight-change dynamics, shifts in adipose-tissue gene expression, and modulation of β3-adrenergic receptor–linked pathways in rodent models of obesity and metabolic dysfunction.2,3
Metabolic Signaling and Receptor Selectivity: Because Frag 176-191 isolates a functionally distinct domain of the hGH molecule, it enables researchers to examine how selective activation of lipolytic signaling compares to full-length hGH exposure. Experimental work has looked at changes in cAMP signaling, free-fatty-acid release, and downstream markers of metabolic stress across a range of preclinical systems.
Emerging and Exploratory Models: More recent investigations have evaluated hGH fragments in combination with delivery platforms such as nanoparticles and in specialized in vitro disease models, including oncology-focused cell lines. These studies are exploratory and are designed to map mechanistic interactions and potential research applications, not to define therapeutic indications.1
Each Frag 176-191 lot is supported by analytical testing for identity and purity using techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry. For the most current COA and testing details associated with a specific lot, qualified research customers may contact Nordsci Peptides support or reference the documentation supplied with their shipment.
Laboratories seeking Frag 176-191 for metabolic and body-composition research should source peptides from suppliers that prioritize analytical transparency and research-grade manufacturing practices. Nordsci Peptides provides high-purity synthetic peptides with robust documentation and batch-level quality data for institutional and professional research teams.
Research Sourcing Considerations:
When procuring Frag 176-191 or other hGH-derived fragments, research groups should confirm that the supplier provides:
Compliance Reminder: Frag 176-191 is supplied exclusively for in vitro and preclinical research applications. It is not approved for human or veterinary use, clinical protocols, or any form of therapeutic administration.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: “in glass”) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
